The candidate vaccine’s next steps will be going through the FDA’s Biologics License Application process.
|Articles|March 8, 2004
New agent draws a bead on colorectal cancer
The FDA recently approved cetuximab (Erbitux, ImClone Systems) for use in combination with irinotecan (Camptosar, Pfizer) for the treatment of epidermal growth factor receptor-1 (EGFR-1)-expressing, metastatic CRC in patients who are refractory to irinotecan-based chemotherapy. Cetuximab was also approved for use as monotherapy for the treatment of EGFR-1-expressing, metastatic CRC in those who are intolerant of irinotecan-based chemotherapy.
Advertisement
Advertisement
Related to this article
The Milken Institute released survey results alongside new data regarding the need for pharmacists in extending effective GLP-1 care.
Through the ACCESS program, Mark Ey, RPh, notes that pharmacies can now start billing for a variety of services they’ve already been providing.
The medication significantly increased risk of pregnancy loss when compared with macrolide antibiotics, amoxicillin, and topical clindamycin for acne.
In part 3, Rebold explores improving the ART formulary protocol through introducing pharmacist-led transition-of-care services.
Our hosts explore why ketone monitoring matters, what pharmacists should know about Libre Duo, and how patient education can support proactive care management.
Mark Ey, RPh, details the patient-focused factors of the ACCESS to Pharmacy Care Program and the ways in which valued care translates to reimbursement.
A new option for adults who have experienced stroke will now be available to further reduce future risk.
Advertisement
Advertisement
Trending on Drug Topics
1
The Pharmacy Model Creating New Billing Pathways, Improved Recognition
2
Doxycycline Use Associated with Higher Risk of Pregnancy Loss
3
Wicked Good Cardiometabolic Chat: Ketone Monitoring in Pharmacy Practice
4
Pharmacist-Led Transitions of Care Could Be Crucial in HIV Treatment
5